Nothing Special   »   [go: up one dir, main page]

HUP0303372A2 - Vakcina - Google Patents

Vakcina

Info

Publication number
HUP0303372A2
HUP0303372A2 HU0303372A HUP0303372A HUP0303372A2 HU P0303372 A2 HUP0303372 A2 HU P0303372A2 HU 0303372 A HU0303372 A HU 0303372A HU P0303372 A HUP0303372 A HU P0303372A HU P0303372 A2 HUP0303372 A2 HU P0303372A2
Authority
HU
Hungary
Prior art keywords
subject
self
vaccine
autoantibodies
immunogens
Prior art date
Application number
HU0303372A
Other languages
English (en)
Inventor
Claire Ashman
James Scott Crowe
Jonathan Henry Ellis
Alan Peter Lewis
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HUP0303372A2 publication Critical patent/HUP0303372A2/hu
Publication of HUP0303372A3 publication Critical patent/HUP0303372A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát saját antigén elleni immunizálásra alkalmas,izolált polipeptid képezi. A találmány tárgyát előnyösen olyan sajátfehérje képezi, amely in vivo beadás esetén autoantitestek képződésétindukálja. A találmány tárgyát előnyösen emberekben az embericitokinek immunogénné alakítása képezi. A találmány tárgyát továbbá azilyen vegyületeket tartalmazó gyógyászati készítmények és ezekalkalmazása gyógyászatban, és ezek előállítására szolgáló eljárásokképezik. Ó
HU0303372A 2001-03-03 2002-03-01 Vaccine HUP0303372A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine

Publications (2)

Publication Number Publication Date
HUP0303372A2 true HUP0303372A2 (hu) 2004-01-28
HUP0303372A3 HUP0303372A3 (en) 2008-06-30

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303372A HUP0303372A3 (en) 2001-03-03 2002-03-01 Vaccine

Country Status (18)

Country Link
US (3) US20050260216A1 (hu)
EP (1) EP1368477A1 (hu)
JP (1) JP4238031B2 (hu)
KR (1) KR20030081490A (hu)
CN (1) CN1543504A (hu)
AU (1) AU2002233560B2 (hu)
BR (1) BR0207819A (hu)
CA (1) CA2439628A1 (hu)
CZ (1) CZ20032373A3 (hu)
GB (1) GB0105360D0 (hu)
HU (1) HUP0303372A3 (hu)
IL (1) IL157498A0 (hu)
MX (1) MXPA03007915A (hu)
NO (1) NO20033882L (hu)
NZ (1) NZ527873A (hu)
PL (1) PL365066A1 (hu)
WO (1) WO2002070711A1 (hu)
ZA (1) ZA200306647B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1532172A2 (en) * 2002-08-30 2005-05-25 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and itstherapeutic use
AU2003260748A1 (en) * 2002-08-30 2004-03-19 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
AU2004213749B2 (en) * 2003-01-31 2010-02-25 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
CA2519114A1 (en) * 2003-03-24 2004-10-07 Mercia Pharma, Inc. Methods and compositions for treating and preventing inflammatory conditions
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
KR101215808B1 (ko) * 2004-06-11 2012-12-26 도꾸리쯔교세이호징 리가가쿠 겐큐소 조절성 세포 리간드를 리포좀에 함유시켜 이루어지는 의약
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PT2486938T (pt) 2006-09-26 2018-06-12 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2008147956A2 (en) * 2007-05-25 2008-12-04 Centocor, Inc. Toll-like receptor 3 modulators and uses thereof
KR101811965B1 (ko) * 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
MX2023008774A (es) * 2021-01-29 2023-08-08 Bayer Animal Health Gmbh Composicion de vacuna para romper la autotolerancia.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
EP1167377B2 (en) * 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
EP1849870A1 (en) * 1995-02-20 2007-10-31 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM)
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
JP2002506618A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 腫瘍自己抗原に対する免疫誘導
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
CA2404763A1 (en) * 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
IL157498A0 (en) 2004-03-28
NZ527873A (en) 2005-12-23
JP4238031B2 (ja) 2009-03-11
KR20030081490A (ko) 2003-10-17
JP2005502314A (ja) 2005-01-27
US20050260216A1 (en) 2005-11-24
CZ20032373A3 (cs) 2004-01-14
PL365066A1 (en) 2004-12-27
NO20033882D0 (no) 2003-09-02
GB0105360D0 (en) 2001-04-18
ZA200306647B (en) 2004-11-26
BR0207819A (pt) 2004-03-02
AU2002233560B2 (en) 2006-09-07
NO20033882L (no) 2003-10-31
EP1368477A1 (en) 2003-12-10
MXPA03007915A (es) 2003-12-04
US20030194391A1 (en) 2003-10-16
US20050186209A1 (en) 2005-08-25
WO2002070711A1 (en) 2002-09-12
CA2439628A1 (en) 2002-09-12
CN1543504A (zh) 2004-11-03
HUP0303372A3 (en) 2008-06-30

Similar Documents

Publication Publication Date Title
HUP0303372A2 (hu) Vakcina
HUP0402067A2 (hu) Oltóanyagok
HUP0202885A2 (hu) Oltóanyagok
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
HUP0202523A2 (hu) Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
HUP0300814A2 (hu) Peptidszelekciós módszer
PL346299A1 (en) Method of dna vaccination
HUP0301447A2 (hu) Tiotrópium- és salmeterolsókat tartalmazó kombinációs gyógyszerkészítmények
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
IN2012DN00313A (hu)
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
CY1108331T1 (el) Προληψη και θεραπεια αμυλοειδογονου νοσου
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
HUP0203972A2 (hu) Antigént és glikolipidet tartalmazó készítmény szublingvális úton történő alkalmazásra
HUP0401903A2 (hu) Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
HUP0402281A2 (hu) Endotelin receptor antagonisták alkalmazása daganatos betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
HUP0204216A2 (en) A new use of antibodies as vaccines
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin
HUP0400698A2 (hu) Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA)
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
HUP0401782A2 (hu) Új, vízmentes kristályos gabapentin formák

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees